Wednesday, June 8th, 2016 - RnR Market Research

The analysts forecast global chronic lymphocytic leukemia therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020. The report covers the present scenario and the growth prospects of the global chronic lymphocytic leukemia therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the generalization of the marketed drugs during the forecast period.

The following companies are the key players in the global chronic lymphocytic leukemia therapeutics market: F. Hoffman-La Roche, AbbVie, Teva Pharmaceuticals, Gilead Sciences, Johnson & Johnson, and Novartis. Other Prominent Vendors in the market are: Altor BioScience, Amgen, Arno Therapeutics, AstraZeneca, Bellicum Pharmaceuticals, Biogen, BioLineRx, Boston Biomedical, Celgene, Emergent BioSolutions, Genzyme, iDD biotech, Immunomedics, Infinity Pharmaceuticals, Innate Pharma, Karyopharm Therapeutics, Ligand Pharmaceuticals, MedImmune, Merck Sharp & Dohme, Molecular Templates Inc., MorphoSys, Ono Pharmaceutical, Portola Pharmaceuticals, Regeneron Pharmaceuticals, Sunesis Pharmaceuticals, TG Therapeutics, TheraMAB, XEME Biopharma, Xencor, and ZIOPHARM Oncology.

 Inquire more about Global Chronic Lymphocytic Leukemia Therapeutics Market 2016-2020 report at @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=607617

According to the chronic lymphocytic leukemia therapeutics market report key growth driver is the special regulatory designations offered to certain drugs. Diseases that affect a small percentage of the population, such as CLL, are treated by a few marketed drugs. A small number of patients implies that there is a small market for these0 drugs, so it may not be profitable for companies to develop these drugs as recovering the R&D expenses would be difficult. To compensate for this limitation and encourage the development of such drugs, regions such as the US and the EU award an Orphan Drug Designation or Breakthrough Therapy Designation to certain drugs.

The global chronic lymphocytic leukemia therapeutics market analyst said a trend that is expected to boost market growth is a rise in the development of combination therapies. Combination therapies for the treatment of CLL were available only in the form of chemotherapy combination drugs. The approved combinations are chlorambucil in combination with prednisone, and a combination of cyclophosphamide with vincristine and prednisone. However, a growing trend of developing combination therapies to treat CLL has been observed. For instance, TG Therapeutics develops TG-1101 in combination with ibrutinib to treat CLL and MCL. Similarly, the company also develops TG-1101 in combination with TGR-1202 to treat CLL and NHL.

Order a copy of report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=607617

Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types:

  • Acute myeloid (or myelogenous) leukemia (AML)
  • Chronic myeloid (or myelogenous) leukemia (CML)
  • Acute lymphocytic (or lymphoblastic) leukemia (ALL)
  • CLL

Further, the report states that one challenge that could restrict market growth is the high cost of therapy. Since R&D costs to develop new drugs is very high, manufacturers pass on costs to buyers, which is a big burden.

File Library

Contact Profile

RnR Market Research


About Us:  

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us: 

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed


Ritesh Tiwari
P: + 1 888 391 5441
W: www.rnrmarketresearch.com/

Keywords

Chronic Lymphocytic Leukemia Therapeutics Market, Chronic Lymphocytic Leukemia Therapeutics industry, global Chronic Lymphocytic Leukemia Therapeutics Market, Chronic Lymphocytic Leukemia Therapeutics Market 2016, market research reports,

Categories

Newsrooms

Sharing

More Formats